Shimelis Nigusse Doni

Shimelis Nigusse Doni

Auto-generated profile, based on publicly available information

Shimelis Nigusse Doni

ALERT Hospital, Addis Ababa

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 October 2023 in NIHR Open Research
Verified
Journal Article
Open access
PDF file
AMAmel Beshir Mohammed
Amel Beshir Mohammed
FMFewzia Shikur Mohammed
Fewzia Shikur Mohammed
FZFeleke Tilahun Zewdu
Feleke Tilahun Zewdu
SNShimelis Doni Nigusse
Shimelis Doni Nigusse
YHYohannes Hailemichael
Yohannes Hailemichael
EGEndalamaw Gadisa
Endalamaw Gadisa
Background: Cutaneous leishmaniasis (CL) is a skin neglected tropical disease, with an estimated 40,000 new cases each year in Ethiopia. CL causes ulcers, nodules, and plaques on the skin, and in some instances the destruction of the nasopharyngeal mucosa and cartilage. Some CL lesions may heal spontaneously, whilst other lesions may require therapies which are associated with discomfort, adverse effects, prolonged treatment, and a frequent lack of a complete response. Scarring, a sequela of CL, causes permanent disfigurement and is associated with stigma linked with a reduction in health-related quality of life. The choice of treatment for CL is based upon factors including the causative species; the number, extent, size, and location of lesions; and the availability of treatments. The development of robust evidence for CL treatment is hindered by a lack of validated and appropriate outcome measures and few data to support hypothesis-generation and trial design. There is a paucity of prospective data with well-defined treatment outcomes for CL caused by L. aethiopica. Aim: The overall aim of this study is to improve the understanding of the health and economic burden of CL. Methods: We have designed an observational, multi-centre cohort study to examine treatment outcomes for CL in Ethiopia which includes clinical outcomes, laboratory outcomes, patient reported outcome measures, scar assessments and cost effectiveness. We aim to recruit up to 750 participants across two hospital sites. We present here the protocol for this cohort study with a 12-month follow up period for each participant. Conclusions: These data will inform the design of randomized controlled trials to evaluate new treatment strategies, with appropriate economic evaluations. This will help improve evidence-based guidelines and support evidence-led policy decisions, not only in Ethiopia but also globally.

30 October 2023 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
SDShimelis Doni
Shimelis Doni
KYKidist Yeneneh
Kidist Yeneneh
YHYohannes Hailemichael
Yohannes Hailemichael
MGMikyas Gebremichael
Mikyas Gebremichael
SSSophie Skarbek
Sophie Skarbek
EGEndalamaw Gadisa
Endalamaw Gadisa
Background: Cutaneous leishmaniasis (CL) is a growing public health threat in Ethiopia. Leishmania aethiopica is the predominant causative organism. Affected individuals develop chronic skin lesions on exposed parts of the body, mostly on the face, which are disfiguring and cause scarring. The effects of CL on the health-related quality of life (HRQoL) of affected individuals has not been assessed in Ethiopia. Objective: To assess HRQoL in adults with active CL at ALERT Hospital, Addis Ababa, Ethiopia. Methods: A cross-sectional study was done using the Amharic version of the Dermatology Life Quality Index (DLQI). Trained health staff administered the DLQI. Results: Three hundred and two adults with active CL participated and all of them exhibited a reduced HRQoL. The median DLQI score was 10 (IQR 8). Almost half of the participants reported very poor HRQoL, 36.4% and 11.3% fell within the very large and extremely large effect categories respectively. DLQI scores were higher (median 18) in patients diagnosed with diffuse cutaneous leishmaniasis (DCL) compared to those with localized cutaneous leishmaniasis (LCL). The DLQI domain of ‘work and school’ was the most affected, scoring 73.3% and 66.6% of total possible score for female and male respectively, followed by that of ‘symptom and feeling’ (at 50.0% and 56.6% for female and male respectively). Men were more affected than women in the domains of ‘leisure’ (P = 0.002) and ‘personal relationships’ (P = 0.001). In the multivariate ordinal logistic regression site of lesion, clinical phenotype and age of participant remained associated with significantly poor HRQoL. Conclusion: The HRQoL impairment associated with CL is significant. Thus, patient-reported outcome measure should be used to assess the efficacy of treatments along with clinical outcome measures.

19 December 2011 in Clinical and Experimental Dermatology
Verified
Journal Article
Closed access
PDF file
SDS. N. Doni
S. N. Doni
AMA. L. Mitchell
A. L. Mitchell
YBY. Bogale
Y. Bogale
SWS. L. Walker
S. L. Walker

3 December 2024 in NIHR Open Research
Verified
Journal Article
Open access
PDF file
AMAmel Beshir Mohammed
Amel Beshir Mohammed
FMFewzia Shikur Mohammed
Fewzia Shikur Mohammed
FZFeleke Tilahun Zewdu
Feleke Tilahun Zewdu
SNShimelis Doni Nigusse
Shimelis Doni Nigusse
YHYohannes Hailemichael
Yohannes Hailemichael
SCSHARP collaboration
SHARP collaboration
Background Cutaneous leishmaniasis (CL) is a skin neglected tropical disease, with an estimated 40,000 new cases each year in Ethiopia. CL causes ulcers, nodules, and plaques on the skin, and in some instances the destruction of the nasopharyngeal mucosa and cartilage. Some CL lesions may heal spontaneously, whilst other lesions may require therapies which are associated with discomfort, adverse effects, prolonged treatment, and a frequent lack of a complete response. Scarring, a sequela of CL, causes permanent disfigurement and is associated with stigma linked with a reduction in health-related quality of life. The choice of treatment for CL is based upon factors including the causative species; the number, extent, size, and location of lesions; and the availability of treatments. The development of robust evidence for CL treatment is hindered by a lack of validated and appropriate outcome measures and few data to support hypothesis-generation and trial design. There is a paucity of prospective data with well-defined treatment outcomes for CL caused by L. aethiopica. Aim The overall aim of this study is to improve the understanding of the health and economic burden of CL. Methods We have designed an observational, multi-centre cohort study to examine treatment outcomes for CL in Ethiopia which includes clinical outcomes, laboratory outcomes, patient reported outcome measures, scar assessments and cost effectiveness. We aim to recruit up to 750 participants across two hospital sites. We present here the protocol for this cohort study with a 12-month follow up period for each participant. Conclusions These data will inform the design of randomized controlled trials to evaluate new treatment strategies, with appropriate economic evaluations. This will help improve evidence-based guidelines and support evidence-led policy decisions, not only in Ethiopia but also globally.

14 May 2025 in NIHR Open Research
Verified
Journal Article
Open access
PDF file
AMAmel Beshir Mohammed
Amel Beshir Mohammed
FMFewzia Shikur Mohammed
Fewzia Shikur Mohammed
FZFeleke Tilahun Zewdu
Feleke Tilahun Zewdu
SNShimelis Doni Nigusse
Shimelis Doni Nigusse
SLSaba Lambert
Saba Lambert
SCSHARP Collaboration
SHARP Collaboration
Introduction Cutaneous leishmaniasis (CL) remains a major public health challenge, especially in endemic regions like Ethiopia, where an estimated 40,000 new cases occur annually. Effective treatment evaluation for CL relies on consistent clinical assessments, yet variability in lesion descriptions can complicate reliable outcome measures. Methods We conducted an inter-reliability study of clinicians’ evaluations of CL lesion morphology and size at ALERT Hospital, Addis Ababa. Twelve clinicians independently examined 12 patients with parasitologically confirmed CL, each clinician assessing lesion morphology, size, and severity. Results We found high consistency in reporting major morphological categories (e.g., plaques) but significant variability in secondary features like dyspigmentation and scale, as well as mucosal involvement. Lesion size measurements showed limited variability, suggesting its reliability as a potential measure for future clinical trials. Disparities in severity assessments highlight the need for a standardized scoring system in CL. Discussion Our findings underscore the importance of training for consistent, high-quality clinical evaluations of CL and suggests that lesion size could be a reproducible outcome measure in treatment efficacy trials.

1 March 2023 in medRxiv
Verified
Preprint
Open access
PDF file
SDShimelis Doni
Shimelis Doni
KYKidist Yeneneh
Kidist Yeneneh
YHYohannes Hailemichael
Yohannes Hailemichael
MGMikyas Gebremichael
Mikyas Gebremichael
SSSophie Skarbek
Sophie Skarbek
EGEndalamaw Gadisa
Endalamaw Gadisa
Background: Cutaneous leishmaniasis (CL) is a growing public health threat in Ethiopia. Leishmania aethiopica is the predominant causative organism. Affected individuals develop chronic skin lesions on exposed parts of the body, mostly on the face, which are disfiguring and cause scarring. The effects of CL on the health-related quality of life (HRQoL) of affected individuals has not been formally assessed in Ethiopia. Objective: To assess HRQoL in adults with active CL at ALERT Hospital, Addis Ababa, Ethiopia. Methods: A cross-sectional study was done using the Amharic version of the Dermatology Life Quality Index (DLQI). Trained health staff administered the DLQI. Results: Three hundred and two adults with active CL participated and all of them exhibited a reduced HRQoL. The median DLQI score was 10 (IQR 8). Almost half of the participants reported very poor HRQoL, 36.4% and 11.3% fell within the very large and extremely large effect categories respectively. DLQI scores were higher (median 18) in patients diagnosed with diffuse cutaneous leishmaniasis (DCL) compared to those with localized cutaneous leishmaniasis (LCL). The DLQI domain of ‘work and school’ was the most affected, scoring 73.3% and 66.6% of total possible core for female and male respectively, followed by that of ‘symptom and feeling’ (at 50.0% and 56.6% for female and male respectively). Men were more affected than women in the domains of ‘leisure’ (P=0.002) and ‘personal relationships’ (P=0.001). In the multivariate ordinal logistic regression site of lesion, clinical phenotype and age remained associated with significantly poor HRQoL. Conclusion: The HRQoL impairment in people affected by CL is significant. This warrants improved care and treatment in Ethiopia, counseling on the nature of CL, therapeutic options as well as clinical outcomes and complications. Importantly, patient-reported outcome measures including the DLQI should be used to assess treatment efficacy patient care algorisms. Plain Language Summary: Cutaneous leishmaniasis (CL) is an important public health problem in Ethiopia with an estimated incidence up to 50,000 cases per year. CL is predominately due to Leishmania aethiopica. The transmission is zoonotic by Phlebotomus longipes and Ph. pedifer , and hyraxes being the incriminated reservoir hosts. The lesion is chronic on the exposed part of the body, commonly on the face. Three main clinical phenotypes are recognized; localized (LCL), mucocutaneous (MCL), and diffuse CL (DCL) cutaneous leishmaniasis. The permanent damage and altered anatomy of the skin, nose, eyelids, ears and lips due to scarring is often associated with stigma. This study aimed to assess the health-related quality of life (HRQoL) using the Amharic version of the Dermatology Life Quality Index (DLQI) in adults diagnosed with active CL. Our results show that the impact on HRQoL associated with CL is large. There was no significant difference between men and women, and urban and rural dwellers. Participants with DCL, the more extensive form of CL, had lower HRQoL compared to those with other forms. Those with lesions on their head and neck regions and younger than 50 year (20 to 49 years age group) had significantly low HRQoL (P<0.05). The reduced HRQoL associated with CL in Ethiopia requires warrants improved, counseling on the nature of CL, therapeutic options as well as clinical outcomes and complications. Importantly, patient-reported outcome measures including the DLQI should be used to assess the efficacy of treatments and patient care algorisms.